Abstract: Slide Presentations |

The Role of Dose Volume in Delivering Albuterol Sulfate With a Low Residual Volume Nebulizer FREE TO VIEW

James B. Fink, MS RRT
Author and Funding Information

Aerogen, Inc., Mountain View, CA


Chest. 2003;124(4_MeetingAbstracts):94S. doi:10.1378/chest.124.4_MeetingAbstracts.94S-b
Text Size: A A A
Published online


PURPOSE:  Rapid efficient delivery of bronchodilators is important in the acute care setting. The standard dose volume of 3 mL with 0.083% albuterol sulfate was established for use with standard nebulizers with residual volumes between 0.8 and 2.0 mL. We wanted to determine the effect of dose volume on inhaled mass and time of administration using a nebulizer with a low (<0.1 mL) residual volume.

METHODS:  A low residual volume nebulizer, Aeroneb® Professional Nebulizer (Aeroneb Pro; Aerogen) was used to aerosolize 2500 μg of albuterol sulfate solution in volumes of 3 mL (0.083% solution) and 0.5 mL (0.5 % solution) while attached to a lung simulator (Hans Rudolph) set to adult tidal breathing parameters (tidal volume 500 mL, rate 15 b/min and inhalation time 35%) of a nonintubated subject. Aerosol was collected on an absolute filter distal to the nebulizer mouthpiece. Drug was eluted from the filter and assayed by HPLC (n=3 for each condition).

RESULTS:  When the 3.0 mL dose of 0.083% albuterol sulfate was aerosolized, the inhaled mass (mean ± SD) deposited on the filter was 575 ± 23 μg representing 23 ± 1% of the total dose, requiring an average administration time of 428 ( ± 17) seconds. The 0.5 mL of 0.5% albuterol sulfate resulted in an inhaled mass of 540 ± 29 μg, or 22 ± 1 % of total dose, requiring an average administration time of 84 (± 10) seconds.

CONCLUSION:  The inhaled mass from 3.0 and 0.5 mL doses containing 2500 μg of albuterol sulfate with the Aeroneb Pro was similar, however there was a five fold increase in administration time required for the larger dose volume.

CLINICAL IMPLICATIONS:  Use of a low residual volume nebulizer may reduce the need to dilute medications, and reduce the time required for administration of bronchodilators.

DISCLOSURE:  J.B. Fink, None.

Tuesday, October 28, 2003

10:30 AM - 12:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543